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Objectives This study tried to determine the association between left atrial (LA) fibrosis, detected using delayed-enhanced mag-
netic resonance imaging (DE-MRI), and the CHADS2 score (point system based on individual clinical risk factors in-
cluding congestive heart failure, hypertension, age, diabetes, and prior stroke) variables, specifically stroke.
Background In patients with atrial fibrillation (AF), conventional markers for the risk of stroke base their higher predictive
effect on clinical features, particularly previous stroke history, and not individual LA pathophysiological proper-
ties. We aimed to determine the association between LA fibrosis, detected using DE-MRI, and the CHADS2 score
variables, specifically stroke.
Methods Patients with AF who presented to the AF clinic and received a DE-MRI of the LA were evaluated. Their risk fac-
tor profiles, including a CHADS2 score, were catalogued. The degree of LA fibrosis was determined as a percent-
age of the LA area. Any history of previous strokes, warfarin use, or cerebrovascular disease was recorded.
Results A total of 387 patients, having a mean age of 65  12 years, 36.8% female, were included in this study. A his-
tory of previous stroke was present in 36 (9.3%) patients. Those patients with previous strokes had a signifi-
cantly higher percentage of LA fibrosis (24.4  12.4% vs. 16.2  9.9%, p  0.01). A larger amount of LA fibro-
sis was also seen in those patients with a higher CHADS2 score (2: 18.7  11.4 vs. 2: 14.7  9.2, p 
0.01). A logistic regression analysis of all variables except strokes (CHAD score) demonstrated that LA fibrosis
independently predicted cerebrovascular events (p  0.002) and significantly increased the predictive perfor-
mance of the score (area under the curve  0.77).
Conclusions Our preliminary, multicenter results suggest DE-MRI–based detection of LA fibrosis is independently associated
with prior history of strokes. We propose that the amount of DE-MRI–determined LA fibrosis could represent a
marker for stroke and a possible therapeutic target with potential applicability for clinical treatment for patients
with AF. (J Am Coll Cardiol 2011;57:831–8) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.09.049Atrial fibrillation (AF) is associated with significant mor-
bidity and mortality, primarily due to the increased risk of
ischemic stroke (1). Patients who suffer from this arrhyth-
mia have a 3% to 4% absolute risk of stroke per year;
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accepted September 13, 2010.however, this risk varies significantly based on individual
clinical features (2). Antithrombotic therapy with the vita-
min K antagonist warfarin is highly effective in preventing
stroke and improving survival (3,4). However, such thera-
pies are associated with life-threatening hemorrhage and
require intensive dosage monitoring (5–7). In an attempt to
spare low-risk AF patients from the cost, inconvenience,
and risk of warfarin therapy, risk stratification schemes have
been developed to tailor anticoagulation therapy to the
patient’s risk (8,9).
Currently, several risk stratification schemes have been
validated and are clinically well established (2,9,10). The
c832 Daccarett et al. JACC Vol. 57, No. 7, 2011
Left Atrium DE-MRI and Stroke Risk February 15, 2011:831–8CHADS2 index is the most
widely used model and was de-
veloped using stroke risk data
from the National Atrial Fibril-
lation Registry. It uses a point
system based on individual clin-
ical risk factors including conges-
tive heart failure, hypertension,
age, diabetes, and prior stroke.
This index is a valuable tool
when predicting cerebrovascular
events in high-risk patients
(9,11); however, clinicians rely
more heavily on clinical judgment when predicting throm-
boembolic risk in moderate-risk patients, a substantial
portion of the AF population (8). Identification of novel,
independent risk factors may supplement existing tools to
help guide clinician judgment in better allocating anticoag-
ulation therapeutic strategies, especially with moderate-risk
AF patients.
It is well established that AF results in remodeling of the
left atrium (LA) structure, including the deposition of
highly current-resistant fibrotic tissue. Such deposits corre-
spond to a low voltage response as well as other changes in
the electrophysiological properties of the LA substrate
(12–14). In spite of this, most AF-thromboembolic risk
factors are based on clinical features rather than individual
LA pathophysiological properties. In part, this is because
analyzing the LA substrate has been challenging. However,
new high temporal and spatial resolution magnetic reso-
nance imaging (MRI) allows for improved visualization and
characterization of the thin AF wall (15). In addition, by
using a novel MRI sequence with delayed-enhancement
(DE-MRI), it has become possible to detect and quantify
LA structural remodeling as a possible determinant of
fibrosis (16). Nevertheless, it has been unclear how the
degree of this substrate change seen in AF patients relates to
stroke and the current risk stratification schemes.
In this study, we aim to ascertain the association of LA
fibrosis and its association with the CHADS2 score vari-
ables and stroke prediction. Furthermore, we provide pre-
liminary evidence that the physiological features of the LA
could be used, in addition to clinical features, when identi-
fying stroke risk in patients. Our goal is to provide the
groundwork for further prospective studies validating the
diagnostic use of LA substrate change, as well as identifying
other potentially useful parameters in the development of
future risk stratification schemes.
Methods
Study design. A cross-sectional analysis was performed
addressing the association between the occurrence of
strokes, the accompanying risk factors, and the amount of
LA structural remodeling determined by DE-MRI in a
Abbreviations
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LA  left atrium/atrial
MRI  magnetic resonance
imaging
TI  inversion time
3D  3-dimensionalpatient undergoing pulmonary vein isolation for AF.
e
qStudy population. Patients, who presented to the Univer-
sity of Utah in Salt Lake City, Utah, and Clinical Center
Coburg, Coburg, Germany, were evaluated prospectively
and consecutively enrolled. All patients underwent DE-
MRI before pulmonary vein isolation and were included as
part of the institutional review board–approved AF research
registry at the University of Utah. The patients’ clinical, AF,
and CHADS2 score characteristics were determined by
clinical examination and systematic chart review. Patients
with cardiac rhythm devices, renal dysfunction (glomerular
filtration rate 60 ml/min), severe claustrophobia, or other
contraindications for MRI were excluded from the study.
Also, patients with a history of stenotic cerebrovascular
disease were excluded from the analysis. A total of 387
patients met these criteria and were included in the final
analysis. A history of stroke was documented for 36 indi-
viduals (9.3%) within the population. To validate the
occurrence of stroke in the included patients, we studied
their previous medical records. The clinical demographics of
the patients are represented in Table 1.
The study protocol was approved by our institutional
review board and was Health Insurance Portability and
Accountability Act (HIPAA)–compliant. Patients were
classified as having either paroxysmal or persistent AF.
Paroxysmal AF was defined as any AF episodes that
self-terminated within 7 days. Persistent AF was defined as




(n  351) p Value
Age, yrs 64 12 70 7 0.001
AF type
Paroxysmal 15 (41.7%) 172 (49%) NS
Persistent 21 (58.3%) 179 (51%) NS
Warfarin use 25 (69.4%) 208 (59%) NS
Female 23 (63.8%) 118 (33.6%) 0.001
Diabetes mellitus 3 (8.3%) 47 (13.4%) NS
Hypertension 24 (66.7%) 204 (58%) NS
Congestive heart failure 2 (5.5%) 36 (10.2%) NS
Age 75 yrs 8 (22.2%) 65 (18.5%) NS
Risk score excluding strokes 1.02 0.65 1 0.9 NS
CHADS2 score 3.02 0.65 1 0.9 0.001
High risk: 2 36 (100%) 90 (25.6%) NS
Moderate risk: 1 — 146 (41.6%) —
Low risk: 0 — 115 (32.8%) —
LA structural remodeling, % 24.4 12.4 16.1 9.8 0.001
LA remodeling stage 2.4 1.1 3.2 0.9 0.001
Stage I: 8.5% (Q1) 1 (2.8%) 96 (27.3%) 0.001
Stage II: 8.6%–16% (Q2) 9 (25%) 88 (25.1%) —
Stage III: 16.1%–21% (Q3) 7 (19.4%) 89 (25.3%) —
Stage IV: 21.1% (Q4) 19 (52.8%) 78 (22.3%) —
Time from stroke to DE-MRI
scan, days
682 265 — —
AF  atrial fibrillation; CHADS2  point system based on individual clinical risk factors including
ongestive heart failure, hypertension, age, diabetes, and prior stroke; DE  delayed-
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February 15, 2011:831–8 Left Atrium DE-MRI and Stroke Riskan episode of AF that lasted longer than 7 days and required
medical or electrical cardioversion for termination.
DE-MRI. DE-MRI was obtained to assess the extent of
LA structural remodeling or nonviable tissue using previ-
ously described methods (16). Briefly, all studies were
performed on either a 1.5-T Avanto or 3-T Verio clinical
scanner (Siemens Medical Solutions, Erlangen, Germany)
using a total imaging matrix phased-array receiver coil. The
scan was acquired, 15 min following contrast agent injection
(0.1 mmol/kg, Multihance, Bracco Diagnostic Inc., Prince-
ton, New Jersey), using a 3-dimensional (3D) inversion
recovery, respiration navigated, electrocardiogram-gated,
gradient echo pulse sequence. We performed a 3D-gated
and respiratory-navigated DE scan on the LA in each
patient. To achieve the best possible images of the LA, the
images of the LA were acquired during the stationary phase,
atrial diastole, and within each R-R interval, the views have
same slice-selective encoding (same Kz) and different phase
encoding (different Ky). Typical acquisition parameters
were: free-breathing using navigator gating, a transverse
imaging volume with voxel size  1.25  1.25  2.5 mm
reconstructed to 0.625  0.625  1.25 mm), inversion
ime (TI)  270 to 310 ms, GRAPPA (GeneRalized
utocalibrating Partially Parallel Acquisition) with r  2
nd 46 reference lines. The TI value for the 3D DE scan
as chosen from TI scout. The optimal TI was determined
n a similar fashion as is used for standard myocardial
iability studies with the TI set to null normal left ventric-
lar myocardium. The time between successive radiofre-
uency pulses (repetition time) and the time between
adiofrequency pulse and measurement (echo time) are
maging parameters that determine the strength of the
ignal; in our study, the repetition time/echo time ratio was
.4:2.3 ms. Electrocardiogram-gating was used to acquire a
mall subset of phase encoding views during the diastolic
hase of the LA cardiac cycle. The time interval between
he R-peak of the electrocardiogram and the start of data
cquisition was defined using the cine images of the LA
ith the sequence optimized for LA diastole in the 2
ifferent patient groups: those in AF and those in regular,
inus rhythm. Data acquisition during LA diastole has been
ptimized for each of these types of rhythms based on
xtensive previous patient studies by determining the opti-
al percent of the R-R interval and acquisition window for
ata collection for each rhythm (AF and normal sinus
hythm). Fat saturation was used to suppress any fat signal.
he echo time of the scan (2.3 ms) was chosen such that fat
nd water are out of phase and the signal intensity of partial
olume fat-tissue voxels was reduced; this allowed improved
elineation of the LA wall boundary. Typical scan time for
he DE-MRI study was 5 to 10 min depending on subject
espiration and heart rate. In addition to the DE-MRI scan,
ontrast-enhanced MR angiography of the LA and pulmo-
ary veins was performed; this imaging modality provided
nitial 3D visualization of the LA and was used to assess
ontrast consistency. wuantitative analysis of LA remodeling. Quantification
f LA remodeling was obtained using previously described
ethods (16). In all DE-MRI images, the epicardial and
ndocardial LA borders were manually contoured with
mage display and analysis software in Seg3D (Scientific
omputing and Imaging Institute, Salt Lake City, Utah).
he relative extent of contrast enhancement within the LA
all was quantified using a threshold-based software algo-
ithm using the pixel intensity distribution of the healthy
nd nonviable myocardial regions using Marrek, Inc. seg-
entation and quantification software (Marrek, Inc., Salt
ake City, Utah).
Patients were assigned to 1 of 4 groups based on quartiles
Q) applied to the DE-MRI LA structural remodeling
istribution. The quartiles were determined and defined to
e the 25th, 50th, and 75th percentile limits of the percent-
ge of LA wall enhancement distribution. Patients with
tage I (Q1) remodeling were defined as those with 8.5%
nhancement, Stage II (Q2) as 8.6% to 16%, Stage III (Q3)
s 16.1% to 21%, and Stage IV (Q4) as 21.1% (Fig. 1).
ualitative analysis of LA remodeling. Qualitative con-
rmation of the percentage of enhancement was performed
or all MRI scans using the 3D visualization capabilities of
orview (Marrek, Inc., Salt Lake City, Utah). A maximum
ntensity projection was used to assess contrast consistency,
ollowed by ray cast volume rendering with an opacity-
Figure 1 Staging of DE-MRI LA Structural Remodeling
Quartile Distribution
Delayed-enhancement magnetic resonance images representing posteroante-
rior views of the left atrium in patients with Stage (quartile) I (A: 2.7% enhance-
ment), Stage II (B: 10.2% enhancement), Stage III (C: 19.4%), and Stage IV
(D: 38.4% enhancement). Left atrial enhancement is represented as green
areas. Color Look-Up Table mask has been applied to the rendered images to
better differentiate enhanced and nonenhanced tissue. DE-MRI  Delayed-
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Left Atrium DE-MRI and Stroke Risk February 15, 2011:831–8Statistical analysis. Normal continuous variables are pre-
sented as the mean  SD. A 1-way analysis of variance was
sed to test for statistical significance; statistical significance
as further addressed using the Tukey-Kramer method to
orrect for multiple comparisons. Categorical variables are
resented as the number and percentage of total. Pearson
hi-square test was used to assess the statistical significance.
nivariate and multivariate logistic regression analyses were
erformed to evaluate the association between clinical vari-
bles and strokes. Differences were considered significant
ith a p value of less than 0.05. All statistical analysis was
erformed using JMP Pro (SAS Institute Inc., Cary, North
arolina).
esults
atient population. A total of 387 patients were included
n our analysis. Five patients with a known history of
tenotic cerebrovascular disease were excluded from the
tudy. A history of stroke was documented for 36 (9.3%)
atients within the population. Patients with a documented
istory of stroke were older and predominantly women
63.8%). There were no significant differences between the
patient groups regarding the type of AF, diabetes, con-
estive heart failure, and hypertension.
The LA size and volume were included in the steps of
odel building and were found to be not significant
redictors (p  0.1). Once LA fibrosis was determined as a
ercentage of the LA area, it was included in the model and
djustment for LA dimensions is assumed.
A fibrosis and stroke. Patients who experienced a prior
troke had a significantly higher percentage of LA fibrosis
han those without history of a previous stroke (24.4 
2.4% vs. 16.1  9.8%, p  0.001) (Fig. 2). Patients with
tage I remodeling experienced very low rates of thrombo-
mbolism (2.8%). In comparison, 52.8% of patients with
xtensive remodeling (Stage IV) had experienced an isch-
mic event. Figure 3 demonstrates the prevalence of stroke
among the various levels of LA structural remodeling. No
specific correlation was found between the time of stroke to
DE-MRI scan and the amount of LA fibrosis (r2  0.002,
 0.76).
A fibrosis and CHADS2 index. Those AF patients with
igher risk factor profiles for stroke (CHADS2 2) had a
ignificantly larger amount of LA fibrosis when compared to
hose patients who had either a moderate or low risk profile
Table 2). Analysis of the risk factor profile based on the
re-determined DE-MRI staging system showed that those
atients with Stage IV remodeling had a significantly higher
HADS2 score than those patients with a lesser degree of
emodeling (Table 3).
A fibrosis and clinical demographics. Atrial fibrillation
atients with more pronounced structural remodeling gen-
rally exhibited persistent rather than paroxysmal AF. As
xpected, warfarin use was more frequent in the moderate-
nd high-risk groups but was not associated with a lower trevalence of stroke. A total of 233 patients had docu-
ented persistent AF, 143 (71.5%) of whom were on
arfarin. In the remaining 154 patients with paroxysmal
F, 90 (48.1%) were on warfarin. The large majority of
atients who were not on warfarin had documented use of
daily aspirin. Therapeutic ranges of patients on warfarin
ere unavailable and therefore not reported.
Age and LA remodeling did not appear to correlate
inearly (r2  0.018). However, those older than 75 years of
age had significantly higher LA fibrosis than younger AF
patients did (19.6  11.9% vs. 16.3  9.8%, p  0.029).
urther analysis by age groups demonstrated a trend toward
arger amounts of structural remodeling (analysis of vari-
nce, p  0.09).
ultivariate analysis. Utilizing univariate and multivari-
te logistic regression analyses that controlled for signifi-
antly different comorbidities and known stroke predictors,
xcluding stroke (CHAD), DE-MRI–quantified LA struc-
Figure 2 Relationship of LA Structural Remodeling and Stroke
Delayed-enhancement magnetic resonance imaging left atrial structural remod-
eling according to the history of strokes (A) and risk profile (B). Patients who
experienced a prior stroke had a significantly higher percentage of LA fibrosis
compared to those without history of a previous stroke (24.4  12.4% vs.
16.1  9.8%, p  0.001). CHADS2  point system based on individual clinical
risk factors including congestive heart failure, hypertension, age, diabetes, and
prior stroke; other abbreviation as in Figure 1.ural remodeling was independently associated with strokes
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February 15, 2011:831–8 Left Atrium DE-MRI and Stroke RiskFigure 3 Incidence of Stroke Among the Various Levels of LA Structural Remodeling
History of stroke (A) and risk score prevalence for stroke (B) according the different delayed-enhancement magnetic resonance imaging left atrial structural remodeling
stages (quartiles). Atrial fibrillation patients with higher risk factor profiles for stroke (CHADS2 2) had a significantly larger amount of left atrial fibrosis when compared






(n  126) p Value
Age, yrs 59.6 11.3 63.7 11.2 70.8 11.1 0.001
AF type
Paroxysmal 60 (52.8%) 77 (52.7%) 50 (39.7%) 0.06
Persistent 55 (47.8%) 69 (47.3%) 76 (60.3%) 0.06
Warfarin use 57 (49.6%) 89 (61%) 87 (69%) 0.008
Female 34 (29.6%) 41 (28.1%) 66 (52.4%) 0.04
Diabetes mellitus 0 (0%) 7 (4.8%) 43 (34%) 0.001
Hypertension 0 (0%) 115 (78.8%) 113 (89.7%) 0.001
Congestive heart failure 0 (0%) 7 (4.8%) 31 (24.6%) 0.001
Age 75 years 0 (0%) 17 (11.6%) 56 (44.4%) 0.001
Risk score excluding strokes 0 0 1 0 1.93 0.80 0.001
Stroke 0 0 0 (0%) 36 (23.4%) NS
Risk score including strokes 0 0 1 0 2.50 0.65 0.001
LA structural remodeling, % 13.91 8.77 15.99 9.71 20.74 11.32 0.001
LA remodeling stage 2.16 1.11 2.40 1.07 2.91 1.07 0.001
Stage I: 8.5% (Q1) 44 (38.3%) 38 (26%) 15 (11.9%) 0.001
Stage II: 8.6%–16% (Q2) 27 (23.5%) 38 (26%) 32 (25.4%) —
Stage III: 16.1%–21% (Q3) 25 (21.7%) 43 (29.5%) 28 (22.2%) —
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Left Atrium DE-MRI and Stroke Risk February 15, 2011:831–8(Table 4). Furthermore, patients with Stage I remodeling
had a protective odds ratio for strokes and those patients
with Stage IV remodeling had nearly 4 times the odds to
have a stroke.
In the univariate model, the odds ratios are Q4 versus Q1
3.4 (p  0.01), Q3 versus Q1  7.5 (p  0.02), Q2 versus
1  9.8 (p  0.04).
ombining clinical with MRI data. When evaluating the
onventional clinical predictors of stroke excluding stroke itself
CHAD score), the predictive statistics of the model signifi-
antly increased after adding MRI-based LA structural remod-
ling (area under the curve increased from 0.58 to 0.72). We
ypothesized a novel clinical stroke prediction index using
umeric allocations for Stage IV remodeling: LA structural
emodeling (2), congestive heart failure (1), hypertension
1), age 75 years (1), and diabetes (1). In addition, we







Age, yrs 62.3 12 66.2
AF type
Paroxysmal 56 (57.7%) 52
Persistent 41 (42.3%) 45
Warfarin use 53 (54.7%) 62
Female 29 (70.1%) 34
Diabetes mellitus 6 (6.2%) 11
Hypertension 46 (47.4%) 59
Congestive heart failure 3 (3.1%) 8
Age 75 years 13 (13.4%) 20
Strokes 1 (1%) 9
Risk score excluding strokes 0.70 0.73 1.01
CHADS2 score 0.72 0.77 1.19
High risk: 2 15 (11.9%) 32
Moderate risk: 1 38 (26%) 38
Low risk: 0 44 (38.3%) 27
LA structural remodeling, % 6.1 1.9 12.1
Abbreviations as in Table 1.
Univariate and Multivariate Logistic RegressionTable 4 Univariate and Multivariate Logistic
Univariate
Variable OR p Value
Persistent vs. paroxysmal AF 1.34 0.40
Warfarin use 0.64 0.22
Female vs. male 3.49 0.001
Diabetes mellitus 0.58 0.38
Hypertension 1.44 0.32
Congestive heart failure 0.51 0.36
Age 75 yrs 1.26 0.59
LA remodeling stage 2.04 0.001
Stage II (Q2) vs. I (Q1) 9.8 0.018
Stage III (Q3) vs. I 7.55 0.03
Stage IV (Q4) vs. I 23.4 0.001Odds ratios (ORs) per unit change.
Abbreviations as in Table 1.ound that this model’s predictive statistics improved the
iagnostic performance when compared with clinical variables
lone (CHAD) [log odds ratio per unit score  1.37, p 
.001 vs. 1.03, p 0.87], with the area under the curve of 0.58.
hen adding the LA fibrosis into the predictive model, the
rea under the curve increased to 0.72.
iscussion
n our study, we found that AF patients who have suffered
n ischemic stroke have significantly higher levels of LA
brosis as quantified by DE-MRI. In addition, we demon-
trated that this LA fibrosis, as a variable of structural atrial
emodeling, could be a valuable tool for clinicians to use in
onjunction with the CHADS2 index for anticoagulation
risk stratification. Further prospective studies are needed;








n  96 p Value
64.7 11.2 65.9 12.6 NS
) 44 (45.8%) 25 (36.1%) 0.01
) 52 (54.2%) 62 (63.9%) 0.01
) 58 (60.4%) 60 (61.9%) NS
32 (33.3%) 46 (47.4%) NS
) 16 (16.7%) 17 (17.5%) NS
) 56 (58.3%) 67 (69.1%) 0.02
9 (9.4%) 18 (18.6%) 0.003
) 17 (17.7%) 23 (23.7%) NS
7 (7.3%) 19 (19.6%) 0.001
7 1.02 0.88 1.28 0.95 0.001
2 1.16 1 1.68 1.2 0.001
) 28 (22.2%) 51 (40.5%) 0.001
43 (29.5%) 27 (18.5%) —
) 25 (21.7%) 19 (16.5%) —
18.5 1.5 30.9 8.8 0.001
ysis for Strokesression Analysis for Strokes
Multivariate
Variable OR p Value
Persistent vs. paroxysmal AF 1.02 0.98
Warfarin use 0.58 0.14
Female vs. male 3.11 0.003
Diabetes mellitus 0.43 0.21
Hypertension 1.35 0.51
Congestive heart failure 0.36 0.19
Age 75 yrs 1.18 0.58
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February 15, 2011:831–8 Left Atrium DE-MRI and Stroke Risknevertheless, this study provides plausible evidence that LA
substrate analysis is an independent risk factor and could
possibly be used in addition to standard clinical variables.
This could potentially lead to an improvement in the
current risk stratification schemes, enhancing our under-
standing of risks leading to thromboembolic events in AF
patients.
It is important to note that prior stroke was not used as a
risk factor, but was rather evaluated more akin to an
outcome variable in our cross-sectional study, though it
should be noted that MRI was performed after the stroke
occurred. Furthermore, significant statistical anomalies in
our sample, such as a 3 times higher stroke rate in women,
correspond to the analysis of population being evaluated for
refractory AF who undergo ablations and cannot be univer-
salized with consideration to selection bias. It is believed
that women with AF are evaluated later than men with AF
are, having the inclination to have more severe phenotypes
of AF and have a larger degree of fibrosis (17–20).
The CHADS2 index is the most accepted, validated risk
tratification model; nonetheless, a recent analysis of the
urrent risk stratification schemes by Fang et al. (8) dem-
nstrated its poor ability to predict strokes. In addition, the
HADS2 scheme has been shown to have a poor predictive
power for moderate-risk patients, who compose the major-
ity of patients stricken with AF (9). Prior investigators have
speculated that additional independent risk factors for
AF-related thromboembolism are not included in current
risk schemes (8). This has led researchers to evaluate various
biomarkers as potential risk factors, including inflammatory
and plasma markers for endothelial dysfunction (10,21,22).
So far, these additional markers have not been shown to
improve the predictive power of the current models.
A systematic review of clinical studies demonstrates that
prior stroke, advanced age, hypertension, and diabetes are
the only consistent independent risk factors for stroke in AF
patients (23). It is important to note that most clinical
studies lack rigorous characterization and direct examina-
tion of the LA substrate and individual tissue characteristics
in AF patients with a history of stroke. Structural and
functional parameters in AF patients have largely been
based on echocardiographic analysis of left ventricular func-
tion and LA size (24,25). Animal models have shown that
an increased atrial size is associated with a higher degree of
interstitial fibrosis resulting in increased collagen and gly-
cogen deposition within the LA wall (26,27). Fatema et al.
(28) evaluated the role of LA volume index as a biomarker
for stroke and reported that LA volume enlargement was
present in a majority of patients (75%) with first-ever
ischemic strokes. This study is consistent with our findings
in demonstrating a correlation between LA structural re-
modeling and ischemic strokes. Of note, it is recognized
that most emboli arise from the LA appendage in AF, so
the relation and this associated mechanism between LA
appendage function and the overall fibrosis in the LA is
presumed and not delineated in this study. mPatient age is a consistent, independent risk factor in all
studies and is associated with an incremental risk increase
for stroke of 1.5% per decade (23). At the present time, it is
not entirely clear how aging relates to the underlying
pathophysiology related to thromboembolism. Although
higher stroke rates may partly be explained by the coexis-
tence of other independent risk factors in the elderly (23), it
may also be due to LA structural changes that occur over
time, especially within the AF population. Goldman et al.
(29) demonstrated that advancing age is independently
associated with reduction of LA appendage velocities. Myo-
cardial fibrosis has been shown to increase with age (30),
and aging has been shown to be associated with increased
LA enlargement and wall thickness (31). Similarly, this
study confirms that, although not a linear relationship,
elderly AF patients have increased LA enhancement seen on
DE-MRI as compared with their younger AF patients. Our
data correlating high levels of LA fibrosis and stroke
demonstrates the adverse relationship seen in progressive
LA substrate remodeling. Therefore, the structural remod-
eling process accentuated in the elderly may lead to LA
substrate and or functional changes resulting in a greater
tendency for thromboembolism.
Study limitations. The main limitation of this study was
that DE-MRI was not performed at the time of stroke; the
time to MRI after the stroke was almost 2 years. We know
that LA enhancement as a determinant of fibrosis is a
dynamic marker and the level of structural remodeling does
not specifically coincide with the time of stroke. It is
important to note that the association between structural
remodeling and stroke could represent a reverse causality
interaction considering that our study results are derived
from retrospective data. However, the strength of associa-
tion among the various stages of LA fibrosis in relationship
to the risk factors and stroke is supportive and supports a
comprehensive prospective evaluation.
It is also of value to note that the greatest predictive
strength of this novel index is evident when applied in
conjunction to the standard clinical variables. Therefore, the
use of MRI-based LA structural remodeling as a single
marker for stroke is not recommended. Also, inclusion of all
clinical predictors into the multivariate analysis may have
led to model overfitting.
Conclusions
Left atrial structural remodeling as a determinant of AF
assessed with DE-MRI is associated with an increased risk
of thromboembolism in AF patients. Clinician use of both
a CHADS2 index and a quantified measure of AF has the
otential to provide a more rigorous risk assessment and
mprove future risk stratification schemes. Further prospec-
ive studies are needed to verify whether AF is a valuable
isk parameter and can be incorporated into the existing
ethodology.
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